logo
Sila Realty Trust Announces First Quarter 2025 Results (CORRECTED)

Sila Realty Trust Announces First Quarter 2025 Results (CORRECTED)

Business Wire09-05-2025

TAMPA, Fla.--(BUSINESS WIRE)-- This press release has been corrected from the May 7, 2025 version to reflect a change in the calculation of loss on extinguishment of debt, which resulted in changes to the balance sheet (other assets increased by $803,000), the income statement (interest expense decreased by $803,000) and the presentation of net income attributable to common stockholders (increased by $803,000, from $0.13 per diluted share to $0.14 per diluted share), funds from operations, or FFO (increased by $803,000, from $0.51 per diluted share to $0.52 per diluted share), and Core FFO (decreased by $24,000). Other than changes to related metrics, there are no other changes.
Sila Realty Trust, Inc. (NYSE: SILA) ('Sila', the 'Company', 'we', or 'us'), a net lease real estate investment trust ('REIT') with a strategic focus on investing in the growing and resilient healthcare sector, today announced operating results for the first quarter ended March 31, 2025.
Highlights for the quarter ended March 31, 2025:
Net income of $7.9 million, or $0.14 per diluted share
Cash net operating income*, or Cash NOI, of $41.2 million
Adjusted funds from operations*, or AFFO, of $29.4 million, or $0.53 per diluted share
Paid and declared cash distributions per share of $0.40 for the quarter
Entered into a senior unsecured revolving credit agreement for aggregate commitments available of up to $600 million, which replaced the Company's prior $500 million revolving line of credit
Acquired a $35.3 million inpatient rehabilitation facility in Knoxville, Tennessee
Subsequent Events
On May 6, 2025, the Company's board of directors, or the Board, approved and authorized a quarterly cash dividend of $0.40 per share of common stock payable on June 4, 2025, to the Company's stockholders of record as of the close of business on May 21, 2025
Acquired a $23.5 million inpatient rehabilitation facility in Dover, Delaware
Management Commentary
'We are pleased with our strong start to 2025 and believe we are making meaningful progress toward achieving our objectives for the year,' stated Michael A. Seton, President and Chief Executive Officer of the Company. 'We believe that our two most recent acquisitions, one located in Knoxville, Tennessee, and the other in Dover, Delaware, exemplify the asset quality that Sila seeks to own. These acquisitions, which are $58.8 million in aggregate purchase price, further demonstrate our ongoing commitment to investing in necessity, purpose-built healthcare real estate that aligns with our strategic focus on lower cost patient settings which support the delivery of specialized care in growing markets.'
'Our portfolio continues to exhibit attractive fundamentals, with a weighted average remaining lease term of 9.7 years and average annual contractual rent escalations of 2.2%. These characteristics, we believe, are indicative of the long-term, durable nature of our cash flows, while the diversity and quality of our tenancy is reflective of our depth of relationships and contacts in the healthcare marketplace. We continue to remain in an extremely strong financial position, with $598.5 million in liquidity and a net debt to EBITDAre ratio of 3.5x as of quarter-end, giving us ample flexibility to continue executing on our disciplined growth strategy. Furthermore, the recent over-subscription and successful recast of our corporate revolving credit facility, we believe, serves as a powerful validation of the confidence our lending partners have in Sila's platform, including our experienced team and portfolio quality.'
*Some of the financial measures throughout this press release are non-GAAP measures. Refer to the Non-GAAP Financial Measures Reconciliation tables at the end of this press release for additional information and reconciliations to the most directly comparable GAAP measure.
Financial Results
Net Income
Our GAAP net income for the first quarter of 2025 was $7.9 million, or $0.14 per diluted share, compared to $15.0 million, or $0.26 per diluted share, for the first quarter of 2024.
Cash NOI
Cash NOI was $41.2 million for the first quarter of 2025, as compared to $46.9 million for the first quarter of 2024. The decrease in Cash NOI is due to receipt of a lease termination fee and the severance fee received from GenesisCare USA, Inc. and its affiliates, or GenesisCare, in the first quarter of 2024, as well as a property vacancy as a result of the Steward Healthcare bankruptcy. This was partially offset by an increase in Cash NOI from acquisitions and first quarter 2025 Cash NOI increases at our other same store properties compared to the first quarter of 2024, primarily as a result of contractual rent increases.
AFFO
AFFO was $29.4 million, or $0.53 per diluted share, during the first quarter of 2025, compared to $38.3 million, or $0.66 per diluted share, during the first quarter of 2024.
Investment Activity
During the quarter ended March 31, 2025, the Company acquired one healthcare property in Knoxville, Tennessee, comprising 70,005 rentable square feet, for a purchase price of $35.3 million. At the time of acquisition, the property was 100% leased under an absolute-net lease to Knoxville Rehabilitation Hospital, LLC with an expiring lease in 2036.
Portfolio
As of March 31, 2025, Sila's well diversified real estate portfolio consisted of 136 properties comprising approximately 5.3 million rentable square feet. The weighted average remaining lease term was approximately 9.7 years with 20.0% of annualized base rent maturing in the next five years and a weighted average fixed rent escalation rate of 2.2%, excluding leases tied to the consumer price index.
As of March 31, 2025, the weighted average percentage of rentable square feet leased was 96.0%.
Balance Sheet and Capital Markets Activities
Sila had a strong balance sheet and liquidity position totaling approximately $598.5 million, consisting of $30.5 million in cash and cash equivalents and $568.0 million of availability under its unsecured credit facility as of March 31, 2025.
On February 18, 2025, the Company entered into a senior unsecured revolving credit agreement, or the 2029 Revolving Credit Agreement, with Bank of America, N.A., as Administrative Agent for the lenders, for aggregate commitments available of up to $600.0 million, which may be increased, subject to lender approval, through incremental term loans and/or revolving loan commitments in an aggregate amount not to exceed $1.5 billion. The maturity date for the 2029 Revolving Credit Agreement is February 16, 2029, which, at the Company's election, may be extended for a period of six-months on no more than two occasions, subject to certain conditions, including a payment of an extension fee. The 2029 Revolving Credit Agreement was entered into to replace the Company's prior $500.0 million revolving line of credit, which had a maturity date of February 15, 2026, with the option to extend for two six-month periods. The Company did not exercise the option to extend. Additionally, upon closing of the 2029 Revolving Credit Agreement, the Company entered into a First Amendment to the senior unsecured amended and restated term loan agreement with Truist Bank, as Administrative Agent, which matures in 2027, and a Second Amendment to the senior unsecured term loan with Truist Bank, as Administrative Agent for the lenders, which matures in 2028, to align certain terms and covenants to the 2029 Revolving Credit Agreement.
Total principal debt outstanding under the unsecured credit facility as of March 31, 2025, was $557.0 million. Of the $557.0 million, $525.0 million was fixed through 10 interest rate swap agreements. The Company's weighted average interest rate on the total principal debt outstanding was 4.7%, including the impact of the interest rate swap agreements, as of March 31, 2025. As of March 31, 2025, net debt to enterprise value was approximately 26.2%.
Distributions
The Company's dividend payout to AFFO ratio was 76.4% for the quarter ended March 31, 2025. On May 6, 2025, the Board approved and authorized a quarterly cash dividend of $0.40 per share of Common Stock payable on June 4, 2025, to the Company's stockholders of record as of the close of business on May 21, 2025. The quarterly cash dividend of $0.40 per share represents an annualized amount of $1.60 per share.
Conference Call and Webcast
A conference call and audio webcast for investors and analysts will be held on Thursday, May 8, 2025, at 11:00 a.m. Eastern Time to discuss our first quarter 2025 operating results and to answer questions. The live and archived webcast can be accessed on the "Events" page of the Company's website at investors.silarealtytrust.com or by direct link at https://events.q4inc.com/attendee/651186381. The archived webcast will be available for 12 months following the call.
About Sila Realty Trust, Inc.
Sila Realty Trust, Inc., headquartered in Tampa, Florida, is a net lease real estate investment trust with a strategic focus on investing in the growing and resilient healthcare sector. The Company invests in high quality healthcare facilities along the continuum of care in the pursuit of generating predictable, durable, and growing income streams. Sila's portfolio comprises high quality tenants in geographically diverse facilities, which are positioned to capitalize on the dynamic delivery of healthcare to patients. As of March 31, 2025, the Company owned 136 real estate properties and two undeveloped land parcels located in 66 markets across the United States. For more information, please visit the Company's website at www.silarealtytrust.com.
Forward-Looking Statements
Certain statements contained herein, other than historical fact, may be considered 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provided by the same. These statements are based on management's current expectations and beliefs and are subject to a number of trends and uncertainties. No forward-looking statement is intended to, nor shall it, serve as a guarantee of future performance. You can identify the forward-looking statements by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'predict,' 'project,' 'seek,' 'should,' 'will' and other similar terms and phrases, including statements about and references to our commitment to investing in necessity, purpose-built healthcare real estate; our strategic focus on lower cost patient settings which support the delivery of specialized care in growing markets; predictions on the durability of our cash flow and financial position; and our ability to continue executing our growth strategy. Forward-looking statements are subject to various risks and uncertainties and factors that could cause actual results to differ materially from the Company's expectations, and you should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and could materially affect the Company's results of operations, financial condition, cash flows, performance or future achievements or events. Additional factors include those described under the section entitled Item 1A. "Risk Factors" of Part I of the Company's 2024 Annual Report on Form 10-K, as filed with the SEC on March 3, 2025, a copy of which is available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
Supplemental Information
The Company routinely provides information for investors and the marketplace through press releases, SEC filings, public conference calls, and the Company's website at investors.silarealtytrust.com. The information that the Company posts to its website may be deemed material. Accordingly, the Company encourages investors and others interested in the Company to routinely monitor and review the information that the Company posts on its website, in addition to following the Company's press releases, public conference calls and SEC filings. A glossary of definitions (including those of certain non-GAAP financial measures) and other supplemental information may be found attached as Exhibit 99.2 to the Current Report on Form 8-K/A filed on May 9, 2025.
Non-GAAP Financial Measures
This press release includes certain financial performance measures not defined by United States generally accepted accounting principles, or GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are included in this press release. We believe such measures provide investors with additional information concerning our operating performance and a basis to compare our performance with the performance of other REITs. Our definitions and calculations of these non-GAAP measures may not be the same as similar measures reported by other REITs.
These non-GAAP financial measures should not be considered as alternatives to net income attributable to common stockholders (determined in accordance with GAAP) as indicators of our financial performance, as alternatives to cash flows from operating activities (determined in accordance with GAAP), or as measures of our liquidity, nor are these measures necessarily indicative of sufficient cash flows to fund all of our needs.
March 31,
2025
2024
Revenue:
Rental revenue
$
48,256
$
50,639
Expenses:
Rental expenses
6,326
5,554
Listing-related expenses

56
General and administrative expenses
5,698
8,174
Depreciation and amortization
17,762
18,898
Impairment losses
3,531

Total operating expenses
33,317
32,682
Other income (expense):
Gain on dispositions of real estate

76
Interest and other income
455
2,241
Interest expense
(7,325
)
(5,294
)
Increase in current expected credit loss reserve
(171
)

Total other expense
(7,041
)
(2,977
)
Net income attributable to common stockholders
$
7,898
$
14,980
Other comprehensive (loss) income - unrealized (loss) gain on interest rate swaps, net
(7,138
)
2,868
Comprehensive income attributable to common stockholders
$
760
$
17,848
Weighted average number of common shares outstanding:
Basic
55,130,665
57,113,041
Diluted
55,620,892
57,661,507
Net income per common share attributable to common stockholders:
Basic
$
0.14
$
0.26
Diluted
$
0.14
$
0.26
Expand
Non-GAAP Financial Measures Reconciliation
A description of FFO, Core FFO and AFFO, and reconciliations of these non-GAAP measures to net income, the most directly comparable GAAP measure, and a description of same store cash NOI and reconciliation of this non-GAAP measure to rental revenue, the most directly comparable GAAP measure, are provided below.
Three Months Ended
March 31,
2025
2024
Net income attributable to common stockholders
$
7,898
$
14,980
Adjustments:
Depreciation and amortization of real estate assets
17,737
18,875
Gain on dispositions of real estate

(76
)
Impairment losses
3,531

FFO (1)
$
29,166
$
33,779
Adjustments:
Listing-related expenses

56
Severance
11
1,863
Write-off of straight-line rent receivables related to prior periods
3

Accelerated stock-based compensation

863
Amortization of above (below) market lease intangibles, including ground leases, net
23
(629
)
Loss on extinguishment of debt
233
228
Increase in current expected credit loss reserve
171

Core FFO (1)
$
29,607
$
36,160
Adjustments:
Deferred rent (2)
319
2,388
Straight-line rent adjustments
(2,391
)
(1,176
)
Amortization of deferred financing costs
652
452
Stock-based compensation
1,261
461
AFFO (1)
$
29,448
$
38,285
Expand
_______________________
(1)
The three months ended March 31, 2024 include $4,098,000 of lease termination fee income received.
(2)
The three months ended March 31, 2024 include a $2,000,000 severance fee received from GenesisCare, and will be recognized in rental revenues over the remaining GenesisCare amended master lease term.
Expand
Funds From Operations (FFO)
FFO is calculated consistent with the National Association of Real Estate Investment Trusts, or NAREIT's, definition, as net income (calculated in accordance with GAAP), excluding gains from sales of real estate assets, impairment of real estate assets and disposition losses from sales of real estate assets, plus depreciation and amortization of real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect FFO on the same basis. We do not have any investments in unconsolidated partnerships or joint ventures. We believe FFO provides a useful understanding of our performance to investors and to our management, and when compared to year over year, FFO reflects the impact on our operations from trends in occupancy. It should be noted, however, that other REITs may not define FFO in accordance with the current NAREIT definition or may interpret the current NAREIT definition differently than the Company does, making comparisons less meaningful.
Core FFO
The Company believes Core FFO is a supplemental financial performance measure that provides investors with additional information to understand the Company's sustainable performance. The Company calculates Core FFO by adjusting FFO to remove the effect of certain GAAP non-cash income and expense items, unusual and infrequent items that are not expected to impact its operating performance on an ongoing basis, items that affect comparability to prior periods and/or items that are not related to its core real estate operations. Excluded items include listing-related expenses, severance, write-off of straight-line rent receivables related to prior periods, accelerated stock-based compensation, amortization of above- and below-market lease intangibles (including ground leases), loss on extinguishment of debt and changes in the current expected credit loss reserve. Other REITs may use different methodologies for calculating Core FFO and, accordingly, the Company's Core FFO may not be comparable to other REITs.
AFFO
The Company believes AFFO is a supplemental financial performance measure that provides investors appropriate supplemental information to evaluate the ongoing operations of the Company. AFFO is a metric used by management to evaluate the Company's dividend policy. The Company calculates AFFO by further adjusting Core FFO for the following items: deferred rent, current period straight-line rent adjustments, amortization of deferred financing costs and stock-based compensation. Other REITs may use different methodologies for calculating AFFO and, accordingly, the Company's AFFO may not be comparable to other REITs.
FFO, Core FFO and AFFO should not be considered to be more relevant or accurate than the GAAP methodology in calculating net income or in its applicability in evaluating the Company's operational performance. The method used to evaluate the value and performance of real estate under GAAP should be considered a more relevant measure of operating performance and more prominent than the non-GAAP FFO, Core FFO and AFFO measures and the adjustments to GAAP in calculating FFO, Core FFO and AFFO.
Three Months Ended
March 31,
2025
2024
Rental revenue
$
48,256
$
50,639
Rental expenses
(6,326
)
(5,554
)
Net operating income
41,930
45,085
Adjustments:
Straight-line rent adjustments, net of write-offs
(2,388
)
(1,176
)
Amortization of above (below) market lease intangibles, including ground leases, net
23
(629
)
Internal property management fee
1,299
1,272
Deferred rent (1)
319
2,388
Cash NOI (1,2)
41,183
46,940
Non-same store cash NOI (2,3)
(3,352
)
(8,235
)
Same store cash NOI (4)
37,831
38,705
Listing-related expenses

(56
)
General and administrative expenses
(5,698
)
(8,174
)
Depreciation and amortization
(17,762
)
(18,898
)
Impairment and disposition losses
(3,531
)

Gain on dispositions of real estate

76
Interest and other income
455
2,241
Interest expense
(7,325
)
(5,294
)
Increase in current expected credit loss reserve
(171
)

Straight-line rent adjustments, net of write-offs
2,388
1,176
Amortization of above (below) market lease intangibles, including ground leases, net
(23
)
629
Internal property management fee
(1,299
)
(1,272
)
Deferred rent (1)
(319
)
(2,388
)
Non-same store cash NOI (2,3)
3,352
8,235
Net income attributable to common stockholders
$
7,898
$
14,980
Expand
_______________________
(1)
The three months ended March 31, 2024 include a $2,000,000 severance fee received from GenesisCare, and will be recognized in rental revenues over the remaining GenesisCare amended master lease term.
(2)
The three months ended March 31, 2024 include $4,098,000 of lease termination fee income received.
(3)
The three months ended March 31, 2024 include $1,471,000 of the total $2,000,000 severance fee received from GenesisCare, and will be recognized in rental revenues over the remaining GenesisCare amended master lease term.
(4)
The three months ended March 31, 2024 include $529,000 of the total $2,000,000 severance fee received from GenesisCare, and will be recognized in rental revenues over the remaining GenesisCare amended master lease term.
Expand
NOI
The Company defines net operating income, or NOI, a non-GAAP financial measure, as rental revenue, less rental expenses, on an accrual basis.
Same Store Properties
In order to evaluate the overall portfolio, management analyzes the NOI of same store properties. The Company defines "same store properties" as properties that were owned and operated for the entirety of both calendar periods being compared and excludes properties under development, re-development, or classified as held for sale. By evaluating same store properties, management is able to monitor the operations of the Company's existing properties for comparable periods to measure the performance of the current portfolio and readily observe the expected effects of new acquisitions and dispositions on net income. There were 125 same store properties for the quarters ended March 31, 2025 and 2024.
Cash NOI
The Company defines Cash NOI as NOI for its properties excluding the impact of GAAP adjustments to rental revenue and rental expenses, consisting of straight-line rent adjustments, net of write-offs, amortization of above- and below-market lease intangibles (including ground leases) and internal property management fees, then including deferred rent received in cash. Cash NOI is used to evaluate the cash-based performance of the Company's real estate portfolio. Same store Cash NOI is calculated to exclude non-same store Cash NOI. The Company believes that NOI and Cash NOI both serve as useful supplements to net income because they allow investors and management to measure unlevered property-level operating results and to compare these results to the comparable results of other real estate companies on a consistent basis. Other real estate companies may use different methodologies for calculating Cash NOI and, accordingly, the Company's Cash NOI may not be comparable to other real estate companies. The Company uses both NOI and Cash NOI to make decisions about resource allocations and to assess the property-level performance of the real estate portfolio.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

WST截止日期:Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊
WST截止日期:Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊

Business Wire

time31 minutes ago

  • Business Wire

WST截止日期:Rosen Law Firm敦促損失超過10萬美元的West Pharmaceutical Services, Inc. (NYSE: WST)股東與法律事務所聯絡以瞭解有關其權利的資訊

紐約--(BUSINESS WIRE)--(美國商業資訊)-- 全球投資人權益法律事務所Rosen Law Firm提醒投資人,一名股東代表在2023年2月16日至2025年2月12日期間購買West Pharmaceutical Services, Inc. (NYSE: WST)證券的投資人提起了集體訴訟。West將自身描述為一家「專注於注射藥物包裝元件、密封解決方案及輸送系統的醫療用品公司」。 如欲瞭解更多資訊,請遞交 表格 、向Phillip Kim律師 寄送電子郵件 ,或致電866-767-3653聯絡我們。 指控內容:Rosen Law Firm正在調查對West Pharmaceutical Services, Inc. (NYSE: WST)在其業務營運方面誤導投資人的指控。 起訴書指稱,在整個集體訴訟期內,被告做出了虛假和誤導性陳述及/或未揭露:(1)儘管聲稱對客戶需求有清晰預判,並將業務阻力歸咎於COVID相關產品的臨時性去庫存,但West實際上在其高利潤率的高價值產品(HVP)組合中持續經歷著顯著的去庫存現象;(2) West的SmartDose裝置雖被標榜為高利潤率的成長型產品,但由於營運效率不彰,對West的利潤率造成了嚴重稀釋;(3)這些利潤率壓力引發了高昂重整活動的風險,包括West退出與長期客戶簽署的持續血糖監測(CGM)合約;以及(4)由於上述原因,被告關於West的業務、營運和前景的正面陳述具有重大誤導性和/或缺乏合理依據。訴訟稱,當市場瞭解真實詳情後,投資人蒙受了損失。 現在怎麼辦:您可能有資格參與針對West Pharmaceutical Services, Inc.的集體訴訟。如果有股東希望擔任該集體訴訟的原告代表,則必須在2025年7月7日之前向法院提出申請。原告代表是指代表其他集體訴訟成員主導訴訟的當事人代表。您無需參與此案即有資格獲得追償。如果您選擇不採取任何行動,您也可以保持缺席集體訴訟成員的身分。如欲瞭解更多資訊,請點選 此處 。 所有代理均為勝訴後取酬。股東無需支付任何費用或開支。 關於Rosen Law Firm:與Rosen Law Firm不同,一些就此等事宜發表公告的法律事務所並不會實際提起證券集體訴訟。身為股東權益訴訟領域公認的領導者, Rosen Law Firm 一直致力於協助股東挽回損失、改善公司治理結構,並追究公司高階主管的違法行為責任。自成立以來,Rosen Law Firm已經為股東挽回了超過10億美元的損失。 請在LinkedIn: 、Twitter: 或Facebook: 上關注我們,以瞭解最新情況。 律師廣告。先前案例不保證可獲致類似結果。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Business Wire

timean hour ago

  • Business Wire

ELV Deadline: Rosen Law Firm Urges Elevance Health, Inc. (NYSE: ELV) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Elevance Health, Inc. (NYSE: ELV) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that, with the Medicaid redetermination process nearly complete, defendants represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. While defendants acknowledged that Medicaid expenses were rising, they repeatedly assured investors that this was adequately reflected in Elevance's guidance for the year. These representations were materially false or misleading. In truth, the redeterminations were causing the acuity and utilization of Elevance's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs. This shift was occurring to a degree that was not reflected in Elevance's rate negotiations with the states or in its financial guidance for 2024. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Elevance Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.

Jefferies Sticks to Their Buy Rating for Halliburton (HAL)
Jefferies Sticks to Their Buy Rating for Halliburton (HAL)

Business Insider

time2 hours ago

  • Business Insider

Jefferies Sticks to Their Buy Rating for Halliburton (HAL)

Jefferies analyst Lloyd Byrne reiterated a Buy rating on Halliburton (HAL – Research Report) today and set a price target of $32.00. The company's shares closed yesterday at $20.57. Confident Investing Starts Here: Byrne covers the Energy sector, focusing on stocks such as Baker Hughes Company, Expand Energy, and Canadian Natural. According to TipRanks, Byrne has an average return of 18.1% and a 50.90% success rate on recommended stocks. In addition to Jefferies, Halliburton also received a Buy from Wells Fargo's Roger Read in a report issued on June 24. However, on June 26, RBC Capital maintained a Hold rating on Halliburton (NYSE: HAL). Based on Halliburton's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.42 billion and a net profit of $204 million. In comparison, last year the company earned a revenue of $5.8 billion and had a net profit of $606 million Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HAL in relation to earlier this year. Last month, Weiss Janet L, a Director at HAL bought 8,550.00 shares for a total of $169,119.00.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store